Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 22,011 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 80,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more

Conditions: Breast Cancer
Interventions: Breast Cancer Screening, Survey/Interview, Focus Group; Diagnostic Test · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 30 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Liver Cancer (Primary and Metastatic), Renal Cancer
Interventions: Not listed
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pregnancy
Interventions: Ceftriaxon, Benzathine penicillin G; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Stony Brook, New York + 2 more

Conditions: Coronary Artery Disease
Interventions: clopidogrel 75 mg, Prasugrel 5 mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Alcohol Use Disorder, Ketosis
Interventions: Kenetik, magnetic resonance imaging scan, Alcohol bar lab, Placebo beverage; Dietary Supplement · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Polyps
Interventions: This is an observational study that has no interventions; Other
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: ALS Therapy Development Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2035
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: 50 mg Usnoflast, 75 mg Usnoflast, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • San Francisco, California + 12 more

Conditions: Cigarette Smoking, Tobacco Use, Cigarette Smoking Behavior
Interventions: HRP Sampling period, NPL Sampling period; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 21 Years and older
Enrollment: 472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovary Cancer, Endometrial Cancer
Interventions: Educational videos, Survey; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions: Microscope integrated optical coherence tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 4 Weeks and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Leptomeningeal Disease
Interventions: MRI Scan, VUEWAY, Gadavist; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Respiratory Infections (ARIs)
Interventions: FebriDx; Device
Lead sponsor: Lumos Diagnostics; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Colton, California • Clearwater, Florida • Lutz, Florida + 7 more

Conditions: Metastases
Interventions: Yttrium-90 (Y-90) resin microspheres; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Carcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
Interventions: Optical Coherence Tomography, Therapeutic Conventional Surgery, Laboratory Evaluation; Procedure · Diagnostic Test
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Achilles Tendinopathy (AT)
Interventions: LipioJoint; Device
Lead sponsor: Joint & Vascular Institute; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Libertyville, Illinois

Conditions: Anxiety, Adolescent Development, Substance Use
Interventions: Trier Social Stress Test; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 14 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: GI-102, Pasritamig; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Nausea and Vomiting Syndrome
Interventions: Transcranial Magnetic Stimulation, TMS; Device
Lead sponsor: David Levinthal; Other
Eligibility: 21 Years to 60 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Melanoma
Interventions: Fianlimab, Cemiplimab, Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Hartford, Connecticut + 9 more

Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions: Intervention 1: Adrenalectomy, Intervention 2: Semaglutide; Procedure · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Individuals on Hormone Therapy Breast Cancer Screening Pilot

Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology

Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder

Metatranscriptomic Markers of Colonic Neoplasia

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

ALS Research Collaborative

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit

Multimedia Aid for Genetic Testing in Gynecologic Oncology

Intraoperative OCT Guidance of Intraocular Surgery II

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

International Registry for Patients With Castleman Disease

FebriDx® Pediatric Validation Study

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

Achilles Tendinopathy Embolization

Adverse Adolescent Pathways to Substance Use

GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

Brain-Stomach Circuits in Chronic Nausea

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion